Lv7
3290 积分 2024-08-25 加入
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
2天前
已完结
Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
2天前
已完结
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
2天前
已完结
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
2天前
已完结
The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights
2天前
已完结
PD-1 inhibition in bone sarcoma and soft-tissue sarcoma
2天前
已完结
The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma
2天前
已完结
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
2天前
已完结
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition
7天前
已完结
RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy
7天前
已完结
皖公网安备34019202002308
